- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: "overactive bladder".
Displaying page 1 of 3.
EudraCT Number: 2010-024271-10 | Sponsor Protocol Number: V00162GL203 | Start Date*: 2011-07-06 |
Sponsor Name:PIERRE FABRE MEDICAMENT | ||
Full Title: Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder | ||
Medical condition: Overactive Bladder symptoms. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-022611-19 | Sponsor Protocol Number: XEN-D0501-CL-03 | Start Date*: 2011-01-07 | |||||||||||
Sponsor Name:Xention Limited | |||||||||||||
Full Title: A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bla... | |||||||||||||
Medical condition: Overactive bladder (OAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004249-33 | Sponsor Protocol Number: A8881001 | Start Date*: 2005-12-14 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination ... | |||||||||||||
Medical condition: Overactive bladder syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) SK (Completed) SE (Completed) CZ (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004854-26 | Sponsor Protocol Number: ELB245201-06 | Start Date*: 2007-02-16 | |||||||||||
Sponsor Name:elbion AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 ... | |||||||||||||
Medical condition: Incontinent Overactive Bladder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006872-39 | Sponsor Protocol Number: DIMS4 | Start Date*: 2008-01-04 | |||||||||||||||||||||
Sponsor Name:Daval International Limited | |||||||||||||||||||||||
Full Title: A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis | |||||||||||||||||||||||
Medical condition: Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002999-34 | Sponsor Protocol Number: Y-79-52120-126 | Start Date*: 2007-12-04 | |||||||||||
Sponsor Name:Ipsen Limited | |||||||||||||
Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ... | |||||||||||||
Medical condition: Idiopathic overactive bladder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000609-23 | Sponsor Protocol Number: BXL-6280213 | Start Date*: 2004-06-25 | |||||||||||
Sponsor Name:BIOXELL SPA | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel-group study to determine the effect of BXL-628 in post-menopausal women with Overactive Bladder (OAB) | |||||||||||||
Medical condition: overactive bladder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001378-26 | Sponsor Protocol Number: 40776ORII/05IA01 | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:Laboratorios SALVAT, S.A. | |||||||||||||
Full Title: A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from... | |||||||||||||
Medical condition: Overactive bladder (OAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) CZ (Completed) HU (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004161-24 | Sponsor Protocol Number: A0221066 | Start Date*: 2015-03-24 |
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | ||
Full Title: An Open-Label, Dose-Escalating Study of the Pharmacokinetics, Safety and Tolerability of Fesoterodine in Pediatric Overactive Bladder Patients Aged 8-17 Years | ||
Medical condition: Overactive bladder (OAB) and Neurogenic Detrusor Over activity | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-001250-24 | Sponsor Protocol Number: 850 1016-1562 | Start Date*: 2005-08-16 |
Sponsor Name:APOGEPHA Arzneimittel GmbH | ||
Full Title: Proof-of-Concept Trial of NS-8 in 3 doses: Comparison of efficacy and tolerability in patients with overactive bladder. | ||
Medical condition: Subjects with overactive bladder syndrome with urinary urge. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021137-32 | Sponsor Protocol Number: CSAF312A2202 | Start Date*: 2011-03-14 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to sp... | |||||||||||||
Medical condition: Neurogenic detrusor overactivity due to spinal cord injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004995-20 | Sponsor Protocol Number: 05/SUR/3360E | Start Date*: 2006-06-08 | |||||||||||
Sponsor Name:R and D Department, Cardiff and the Vale NHS Trust | |||||||||||||
Full Title: A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (500 Units Dysport®) for the Management of Idiopathic Overacti... | |||||||||||||
Medical condition: Idiopathic Overactive bladder syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003929-30 | Sponsor Protocol Number: 1 | Start Date*: 2022-10-14 |
Sponsor Name:Ligalli BV | ||
Full Title: INFLUENCE OF OXYBUTYNIN - MEDRING LIGALLI ON OVERACTIVE BLADDER SYMPTOMS IN WOMEN | ||
Medical condition: urinary urge incontinence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-006201-12 | Sponsor Protocol Number: 003 | Start Date*: 2007-01-10 | |||||||||||
Sponsor Name:MERCK SHARP DOHME | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder | |||||||||||||
Medical condition: overactove bladder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005431-97 | Sponsor Protocol Number: B3P104833 | Start Date*: 2006-03-14 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: An Eight-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Dose Ranging Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile... | ||
Medical condition: Overactive bladder (OAB) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FI (Completed) DE (Completed) SI (Completed) LV (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005868-93 | Sponsor Protocol Number: AV608-106 | Start Date*: 2006-05-15 |
Sponsor Name:AVERA PHARMACEUTICALS INC. | ||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor Overactivity | ||
Medical condition: Idiopathic Detrusor Overactivity (Overactive Bladder) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023210-31 | Sponsor Protocol Number: Y52-52120-155 | Start Date*: 2012-02-24 | |||||||||||
Sponsor Name:Ipsen Innovation | |||||||||||||
Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT... | |||||||||||||
Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016800-22 | Sponsor Protocol Number: I1A-MC-BPAE | Start Date*: 2010-05-14 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006656-35 | Sponsor Protocol Number: A3711047 | Start Date*: 2007-06-12 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage L... | |||||||||||||
Medical condition: Storage male lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) FI (Completed) DE (Completed) GB (Completed) GR (Completed) LV (Completed) IT (Completed) SK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003407-12 | Sponsor Protocol Number: 191622-518 | Start Date*: 2008-02-19 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin ... | |||||||||||||
Medical condition: Neurogenic detrusor overactivity as a result of spinal cord injury, in patients with urinary incontinence, who have not been adequately managed with anticholinergic therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
